Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin R Farlow

Showing results (21-30 of 189) with videos related to

Pageof 19
Sort By:
Dementia and Geriatric Cognitive Disorders|August 10, 2005
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysisMartin R Farlow, Gary W Small, Peter Quarg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?Marwan N Sabbagh, Martin R Farlow, Normal Relkin, et al.
Current Alzheimer Research|December 20, 2014
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factorGeorge T Grossberg, Martin R Farlow, Xiangyi Meng, et al.
Journal of Alzheimer'S Disease : JAD|September 1, 2005
The use of memantine in dementia with Lewy bodiesMarwan N Sabbagh, Ann Marie Hake, Sahir Ahmed, et al.
American Journal of Alzheimer'S Disease and Other Dementias|April 16, 2010
Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's diseaseMartin R Farlow, Jeffrey L Cummings, Jason T Olin, et al.
International Journal of Geriatric Psychiatry|November 10, 2011
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapyMartin R Farlow, George T Grossberg, Xiangyi Meng, et al.
Current Medical Research and Opinion|September 11, 2010
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's diseaseMartin R Farlow, George Grossberg, Serge Gauthier, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 23, 2016
Tau Imaging in Alzheimer's Disease Diagnosis and Clinical TrialsJared R Brosch, Martin R Farlow, Shannon L Risacher, et al.
CNS Neuroscience & Therapeutics|October 19, 2010
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementiaFrederick A Schmitt, Martin R Farlow, Xiangyi Meng, et al.
CNS Neuroscience & Therapeutics|August 9, 2013
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementiaMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
Pageof 19

Showing results (21-30 of 189) with videos related to

Sort By:
Pageof 19
Dementia and Geriatric Cognitive Disorders|August 10, 2005
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysisMartin R Farlow, Gary W Small, Peter Quarg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?Marwan N Sabbagh, Martin R Farlow, Normal Relkin, et al.
Current Alzheimer Research|December 20, 2014
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factorGeorge T Grossberg, Martin R Farlow, Xiangyi Meng, et al.
Journal of Alzheimer'S Disease : JAD|September 1, 2005
The use of memantine in dementia with Lewy bodiesMarwan N Sabbagh, Ann Marie Hake, Sahir Ahmed, et al.
American Journal of Alzheimer'S Disease and Other Dementias|April 16, 2010
Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's diseaseMartin R Farlow, Jeffrey L Cummings, Jason T Olin, et al.
International Journal of Geriatric Psychiatry|November 10, 2011
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapyMartin R Farlow, George T Grossberg, Xiangyi Meng, et al.
Current Medical Research and Opinion|September 11, 2010
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's diseaseMartin R Farlow, George Grossberg, Serge Gauthier, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 23, 2016
Tau Imaging in Alzheimer's Disease Diagnosis and Clinical TrialsJared R Brosch, Martin R Farlow, Shannon L Risacher, et al.
CNS Neuroscience & Therapeutics|October 19, 2010
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementiaFrederick A Schmitt, Martin R Farlow, Xiangyi Meng, et al.
CNS Neuroscience & Therapeutics|August 9, 2013
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementiaMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
Pageof 19